The criteria used to assess the antiepileptic performance of the treatment were as follows: seizure severity and latency to the first epileptic seizure within three hours of SE, 14 or 21 days after treatment with the siRNA-GluN1/transfection system. Here, GRIN1 is linked to Seizure.